Atlas Trials

A Safety and Tolerability Study of Pemigatinib in Japanese Subjects With Advanced Malignancies - (FIGHT-102)

Clinical trial NCT03235570 · COMPLETED

Trial details

NCT number
NCT03235570
Sponsor
Incyte Corporation
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Solid Tumors
Start date
2017-08-01
Primary completion
2020-03-04
Enrollment
44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.